Klotho Neurosciences, Inc. (NASDAQ: KLTO) has announced a strategic partnership with AAVnerGene Inc., a biotech company based in Rockville, MD, known for its advanced AAV manufacturing and tissue-targeted delivery technologies. This collaboration aims to address challenges in AAV gene therapy, including high drug costs and dose-related toxicity, by leveraging AAVnerGene's proprietary platforms. The partnership will utilize the AAVone system to reduce manufacturing costs and the ATHENA platform for efficient tissue-targeted delivery. Klotho Neurosciences plans to apply these technologies to accelerate the development of its gene therapy candidates, such as KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS, and KLTO-303 for aging-related conditions. The collaboration is expected to result in more affordable and innovative treatments for both rare and common neurological diseases.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。